Mackenzie Financial Corp Takes $51,000 Position in Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Mackenzie Financial Corp purchased a new stake in Poseida Therapeutics, Inc. (NASDAQ:PSTX) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 17,616 shares of the company’s stock, valued at approximately $51,000.

Several other large investors have also recently made changes to their positions in the stock. The Manufacturers Life Insurance Company lifted its holdings in shares of Poseida Therapeutics by 14.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 28,520 shares of the company’s stock worth $83,000 after acquiring an additional 3,552 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of Poseida Therapeutics by 4.2% in the 2nd quarter. Rhumbline Advisers now owns 97,012 shares of the company’s stock worth $283,000 after acquiring an additional 3,875 shares during the last quarter. American Century Companies Inc. lifted its holdings in shares of Poseida Therapeutics by 5.9% in the 2nd quarter. American Century Companies Inc. now owns 90,487 shares of the company’s stock worth $264,000 after acquiring an additional 5,023 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Poseida Therapeutics by 1.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 599,812 shares of the company’s stock worth $1,749,000 after acquiring an additional 9,672 shares during the last quarter. Finally, Bayesian Capital Management LP acquired a new position in shares of Poseida Therapeutics in the 1st quarter worth approximately $33,000. 46.87% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Poseida Therapeutics in a report on Tuesday, August 6th.

Poseida Therapeutics Price Performance

Poseida Therapeutics stock opened at $2.57 on Wednesday. The firm has a market cap of $249.62 million, a PE ratio of -2.24 and a beta of 0.51. Poseida Therapeutics, Inc. has a 52-week low of $1.83 and a 52-week high of $4.27. The company has a quick ratio of 2.48, a current ratio of 2.48 and a debt-to-equity ratio of 0.97. The company’s 50 day moving average is $2.97 and its two-hundred day moving average is $2.91.

Poseida Therapeutics (NASDAQ:PSTX) last released its earnings results on Monday, August 5th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.11. The company had revenue of $25.97 million for the quarter, compared to analyst estimates of $13.75 million. Poseida Therapeutics had a negative net margin of 127.48% and a negative return on equity of 121.01%. On average, research analysts expect that Poseida Therapeutics, Inc. will post -1.57 EPS for the current fiscal year.

Poseida Therapeutics Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.